Navigation Links
Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
Date:9/17/2007

VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), announced today that it reached a favourable agreement with Johnson & Johnson's subsidiary, Conor Medsystems ("Conor") to settle all outstanding patent litigation with respect to Conor's CoStar(R) paclitaxel stent.

"With this agreement now in place, Angiotech expects that the resources required to defend and enforce our intellectual property should decrease," said Dr. William Hunter, President and CEO of Angiotech.

At the time of the settlement, there was ongoing litigation in three jurisdictions: the UK, the Netherlands and Australia.

Note on Forward Looking Statements:

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2007 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.

Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to integrate into our business the operations of American Medical Instruments Holdings, Inc. ("AMI"); our ability to achieve the operational and other synergies and the other commercial or financial benefits expected as a result of the acquisition of AMI; and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this prospectus to reflect future results, events or developments.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Jodi Regts, Sr. Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals Inc., (604) 221-7930, jregts@angio.com; Deirdre Neary, Manager, Investor Relations Angiotech Pharmaceuticals, Inc. (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Douglas Stewart reaches distribution pact with digital video firm
2. Avolte Venture Partners reaches capital goal
3. TomoTherapys 100th radiology system reaches public sector
4. Global information firm reaches diverse markets
5. Learning how far your message reaches by Googling yourself
6. Biotech industry reaches midpoint in 50-year maturation cycle
7. Doyle Preaches Importance of Tech Industry at Summit
8. WARF enters licensing agreements for stem cell products
9. Quick peeks, Clawback Agreements, and the rules of electronic discovery
10. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
11. WARF expands license agreement with Advanced Cell Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , ... Inc. (ESI). Mr. Murray will bring valuable expertise ... experience in leading international business teams. As the National Division Leader, ... uphold Eurofins, status as the global leader in bio-analytical testing services. ... , , ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, ... essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's ... is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket ...
(Date:12/8/2016)... December 8, 2016 Oxford Gene ... customisable SureSeq™ NGS panel range with the launch of the ... cost-effective study of variants in familial hypercholesterolemia (FH). The panel ... detection on a single small panel and allows customisation by ... includes all exons for LDLR , P ...
(Date:12/8/2016)... ... 08, 2016 , ... KBioBox llc announced today the launch ... developed a sophisticated “3 click” gene dditing off target analysis program and a ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical ...
Breaking Biology Technology:
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... -- Research and Markets has announced the addition of ... to their offering. ... The global bioinformatics ... USD 6.21 Billion in 2016, growing at a CAGR of 21.1% ... market is driven by the growing demand for nucleic acid and ...
Breaking Biology News(10 mins):